Protective role of neuronal and lymphoid cannabinoid CB2 receptors in neuropathic pain

  1. David Cabañero
  2. Angela Ramírez-López
  3. Eva Drews
  4. Anne Schmöle
  5. David M Otte
  6. Agnieszka Wawrzczak-Bargiela
  7. Hector Huerga Encabo
  8. Sami Kummer
  9. Antonio Ferrer-Montiel
  10. Ryszard Przewlocki
  11. Andreas Zimmer
  12. Rafael Maldonado  Is a corresponding author
  1. Universitat Pompeu Fabra, Spain
  2. University of Bonn, Germany
  3. Polish Academy of Sciences, Poland
  4. Universidad Miguel Hernández, Spain

Abstract

Cannabinoid CB2 receptor (CB2) agonists are potential analgesics void of psychotropic effects. Peripheral immune cells, neurons and glia express CB2, however the involvement of CB2 from these cells in neuropathic pain remains unresolved. We explored spontaneous neuropathic pain through on-demand self-administration of the selective CB2 agonist JWH133 in wild-type and knockout mice lacking CB2 in neurons, monocytes or constitutively. Operant self-administration reflected drug-taking to alleviate spontaneous pain, nociceptive and affective manifestations. While constitutive deletion of CB2 disrupted JWH133-taking behavior, this behavior was not modified in monocyte-specific CB2 knockouts and was increased in mice defective in neuronal CB2 knockouts suggestive of increased spontaneous pain. Interestingly, CB2-positive lymphocytes infiltrated the injured nerve and possible CB2transfer from immune cells to neurons was found. Lymphocyte CB2depletion also exacerbated JWH133 self-administration and inhibited antinociception. This work identifies a simultaneous activity of neuronal and lymphoid CB2that protects against spontaneous and evoked neuropathic pain.

Data availability

All experimental data and statistical analyses of this study are included in the manuscript and its supplementary files. Raw data and results of statistical analyses are provided in the Source Data File and its containing data sheets.

Article and author information

Author details

  1. David Cabañero

    Laboratory of Neuropharmacology, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1133-0908
  2. Angela Ramírez-López

    Laboratory of Neuropharmacology, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain
    Competing interests
    The authors declare that no competing interests exist.
  3. Eva Drews

    Institute of Molecular Psychiatry, University of Bonn, Bonn, Germany
    Competing interests
    The authors declare that no competing interests exist.
  4. Anne Schmöle

    Institute of Molecular Psychiatry, University of Bonn, Bonn, Germany
    Competing interests
    The authors declare that no competing interests exist.
  5. David M Otte

    Institute of Molecular Psychiatry, University of Bonn, Bonn, Germany
    Competing interests
    The authors declare that no competing interests exist.
  6. Agnieszka Wawrzczak-Bargiela

    Department of Molecular Neuropharmacology, Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland
    Competing interests
    The authors declare that no competing interests exist.
  7. Hector Huerga Encabo

    Immunology Unit, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain
    Competing interests
    The authors declare that no competing interests exist.
  8. Sami Kummer

    Laboratory of Neuropharmacology, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain
    Competing interests
    The authors declare that no competing interests exist.
  9. Antonio Ferrer-Montiel

    Institute of Research, Development and Innovation in Healthcare Biotechnology of Elche (IDiBE), Universidad Miguel Hernández, Elche, Alicante, Spain
    Competing interests
    The authors declare that no competing interests exist.
  10. Ryszard Przewlocki

    Department of Molecular Neuropharmacology, Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland
    Competing interests
    The authors declare that no competing interests exist.
  11. Andreas Zimmer

    Institute of Molecular Psychiatry, University of Bonn, Bonn, Germany
    Competing interests
    The authors declare that no competing interests exist.
  12. Rafael Maldonado

    Laboratory of Neuropharmacology, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain
    For correspondence
    rafael.maldonado@upf.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4359-8773

Funding

European Commission (FP7-602891-2)

  • Rafael Maldonado

Instituto de Salud Carlos III (RD12/0028/0023/FEDER)

  • Rafael Maldonado

Ministerio de Economía y Competitividad (SAF2014-59648-P)

  • Rafael Maldonado

Generalitat de Catalunya (2014-SGR-1547)

  • Rafael Maldonado

Generalitat de Catalunya (2018 FI_B 00207)

  • Angela Ramírez-López

Polish Ministry of Science and Education (3070/7.PR/2014/2)

  • Ryszard Przewlocki

Universidad Miguel Hernandez (UMH-PAR2019)

  • Antonio Ferrer-Montiel

Spanish Ministry of Science, Innovation and Universities (RTI2018-097189-B-C21)

  • Antonio Ferrer-Montiel

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: Animal handling and experiments were in accordance with protocols approved by the respective Animal Care and Use Committees of the PRBB, Departament de Territori i Habitatge of Generalitat de Catalunya and the Institute of Molecular Psychiatry and were performed in accordance with the European Communities Council Directive (2010/63/EU).

Copyright

© 2020, Cabañero et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,600
    views
  • 253
    downloads
  • 34
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. David Cabañero
  2. Angela Ramírez-López
  3. Eva Drews
  4. Anne Schmöle
  5. David M Otte
  6. Agnieszka Wawrzczak-Bargiela
  7. Hector Huerga Encabo
  8. Sami Kummer
  9. Antonio Ferrer-Montiel
  10. Ryszard Przewlocki
  11. Andreas Zimmer
  12. Rafael Maldonado
(2020)
Protective role of neuronal and lymphoid cannabinoid CB2 receptors in neuropathic pain
eLife 9:e55582.
https://doi.org/10.7554/eLife.55582

Share this article

https://doi.org/10.7554/eLife.55582

Further reading

    1. Neuroscience
    Paul I Jaffe, Gustavo X Santiago-Reyes ... Russell A Poldrack
    Research Article

    Evidence accumulation models (EAMs) are the dominant framework for modeling response time (RT) data from speeded decision-making tasks. While providing a good quantitative description of RT data in terms of abstract perceptual representations, EAMs do not explain how the visual system extracts these representations in the first place. To address this limitation, we introduce the visual accumulator model (VAM), in which convolutional neural network models of visual processing and traditional EAMs are jointly fitted to trial-level RTs and raw (pixel-space) visual stimuli from individual subjects in a unified Bayesian framework. Models fitted to large-scale cognitive training data from a stylized flanker task captured individual differences in congruency effects, RTs, and accuracy. We find evidence that the selection of task-relevant information occurs through the orthogonalization of relevant and irrelevant representations, demonstrating how our framework can be used to relate visual representations to behavioral outputs. Together, our work provides a probabilistic framework for both constraining neural network models of vision with behavioral data and studying how the visual system extracts representations that guide decisions.

    1. Neuroscience
    Aneri Soni, Michael J Frank
    Research Article

    How and why is working memory (WM) capacity limited? Traditional cognitive accounts focus either on limitations on the number or items that can be stored (slots models), or loss of precision with increasing load (resource models). Here, we show that a neural network model of prefrontal cortex and basal ganglia can learn to reuse the same prefrontal populations to store multiple items, leading to resource-like constraints within a slot-like system, and inducing a trade-off between quantity and precision of information. Such ‘chunking’ strategies are adapted as a function of reinforcement learning and WM task demands, mimicking human performance and normative models. Moreover, adaptive performance requires a dynamic range of dopaminergic signals to adjust striatal gating policies, providing a new interpretation of WM difficulties in patient populations such as Parkinson’s disease, ADHD, and schizophrenia. These simulations also suggest a computational rather than anatomical limit to WM capacity.